We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ANDA Reviews Bogged Down By Missing, Buried Compliance Data: FDA
ANDA Reviews Bogged Down By Missing, Buried Compliance Data: FDA
May 25, 2012
Generic-drug makers are contributing to review delays because, intentionally or not, their ANDAs too often fail to provide a full list of personnel and facilities involved in drug manufacturing and testing, FDA officials say.